ALK and non-small cell lung carcinoma: This multicenter, prospective cohort study compared the clinical outcomes of alectinib and brigatinib in this setting.<h4>Methods</h4>Patients with stage IV ALK-positive NSCLC who progressed on crizotinib were enrolled and treated with either brigatinib or alectinib.